Company intelligence / Profile preview

ADRY+

Tokyo, Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

ADRY+ is a Japanese biotechnology company focused on the development and commercialization of anti-aging and longevity solutions centered around Nicotinamide Adenine Dinucleotide (NAD+) precursors. The company specializes in high-purity Nicotinamide Mononucleotide (NMN) supplements and related healthcare products designed to support cellular health and metabolic function. ADRY+ leverages scientific research to provide consumer-facing wellness products that target the biological mechanisms of aging. Their business model combines direct-to-consumer sales with ongoing research into the therapeutic potential of NAD+ boosting molecules.

Therapeutic areas: NeurologyMetabolic DisordersOther
Modalities: Small moleculeNutraceutical
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on ADRY+.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADRY+.

Explore the full profile